-+ 0.00%
-+ 0.00%
-+ 0.00%

Rein Therapeutics says FDA grants Fast Track status to LTI-03 in idiopathic pulmonary fibrosis

PUBT·08/20/2026 12:02:54
Listen to the news
Rein Therapeutics says FDA grants Fast Track status to LTI-03 in idiopathic pulmonary fibrosis
  • Rein Therapeutics secured FDA Fast Track designation for LTI-03 in idiopathic pulmonary fibrosis, a move that could accelerate development timelines.
  • Enrollment continues in the Phase 2 RENEW trial across five countries, positioning the program for a key clinical readout.
  • Interim results have not been presented yet; data are expected in the second half of 2026.
  • The designation signals regulatory support for a potential therapy aimed at slowing progression while supporting lung repair in a high-mortality disease.
  • LTI-03 previously received FDA Orphan Drug designation in the same indication, strengthening its regulatory profile ahead of later-stage decisions.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rein Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608200800PRIMZONEFULLFEED9813115) on August 20, 2026, and is solely responsible for the information contained therein.